Molecular genetics of Ewing sarcoma, model systems and finding novel (immuno-) therapeutic targets

Abstract

Ewing sarcoma (EWS) is a bone- and soft tissue tumour affecting primarily children and young adults. A quarter of patients present with metastases at the time of diagnosis and have a poor outlook in terms of overall survival. Efforts are made across the field to gain deeper insight in the genetics of this enigmatic neoplasm. EWS is characterized by presence of an oncogenic translocation gene, EWSR1-ETS. In addition, there are a limited number of known recurrent DNA copy number variations and mutations. Subsequent of the above, the epigenetic profile of EWS is subject of interest. In this review, we summarize the current available knowledge on the genetics underpinning EWS, explore the current knowledge of its epigenetic profile, discuss in vitro and in vivo model systems, and explore the unravelling knowledge of potential targets for treatment including recent insights into potential immunotherapy.

Keywords

Bone neoplasm / Ewing sarcoma / genetic translocation / DNA copy number variation / mutation

References

[1] FletcherCDM,HogendoornPCW.WHO classification of tumours of soft tissue and bone, 4th ed.2013;Lyon, FranceIARC Press

[2] EwingJ.Diffuse endothelioma of bone.Proc N Y Path1921;21:17-24

[3] Lizard-NacolS,JustraboE.Immunologic characterization of Ewing's sarcoma using mesenchymal and neural markers.Am J Pathol1989;135:847-55 PMCID:PMC1880093

[4] MaurerHM.Solid tumors in children.N Engl J Med1978;299:1345-8

[5] ToomeyEC,LessnickSL.Recent advances in the molecular pathogenesis of Ewing's sarcoma.Oncogene2010;29:4504-16 PMCID:PMC3555143

[6] GeensL,GeertV.An unusual location of extraosseous Ewing's sarcoma.Case Rep Oncol2013;6:293-302 PMCID:PMC3725030

[7] PizzoPA.Principles and Practice of Pediatric Oncology, 6th ed.2011;Philadelphia, United StatesWolters Kluwer Health/Lippincott Williams & Wilkins

[8] BacciG,LonghiA,De PaolisM,VersariM,BriccoliA.Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997.Ann Oncol2003;14:1654-9

[9] MeyersPA,LadanyiM,SailerSL,BakerDL,GerbingRB,HerzogCE,Liu-MaresW,SiegerL,GorlickRG.High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis.J Clin Oncol2001;19:2812-20

[10] BernsteinM,PaulussenM,SchuckA,JuergensH.Ewing's sarcoma family of tumors: current management.Oncologist2006;11:503-19

[11] BalamuthNJ.Ewing's sarcoma.Lancet Oncol2010;11:184-92

[12] HamiltonSN,HasanH,GoddardK.Long-term outcomes and complications in pediatric Ewing sarcoma.Am J Clin Oncol2017;40:423-8

[13] PaulussenM,BurdachS,Dockhorn-DworniczakB,FröhlichB,ZoubekA.Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies.European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol1998;9:275-81

[14] MiserJS,TarbellNJ,FryerCJ,GebhardtMC,PerlmanEJ,DonaldsonSS,RausenAR,GrierHE.Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.J Clin Oncol2004;22:2873-6

[15] DrabkoK,BilskaK,UssowiczM,WojcikB,GorczynskaE,WozniakW,WysockiM,KowalczykJ.Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma.Bone Marrow Transplant2012;47:1530-4

[16] LadensteinR,Le DeleyMC,PaulussenM,van den BergH,HjorthL,LewisI,JürgensH.Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial.J Clin Oncol2010;28:3284-91

[17] JuergensC,LewisI,PaulussenM,MichonJ,JuergensH.Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial..Pediatr Blood Cancer2006;47:22-9

[18] BaillyRA,ZucmanJ,DelattreO,ThomasG.DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma.Mol Cell Biol1994;14:3230-41 PMCID:PMC358690

[19] ZucmanJ,DesmazeC,PlougastelB,ZuckerJM,SheerD.Combinatorial generation of variable fusion proteins in the Ewing family of tumours.EMBO J1993;12:4481-7 PMCID:PMC413872

[20] SorensenPH,Lopez-TerradaD,TricheTJ.A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG.Nat Genet1994;6:146-51

[21] OhnoT,ReddyES.EWS/Fli-1 chimeric protein is a transcriptional activator.Cancer Res1993;53:5859-63

[22] ArvandA.Biology of EWS/ETS fusions in Ewing's family tumors.Oncogene2001;20:5747-54

[23] SankarS,BearssJ,HoffmanLM,BeckerleMC,LessnickSL.Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.Clin Cancer Res2014;20:4584-97 PMCID:PMC4155010

[24] TomazouEM,SchmidlC,SchöneggerA,KubicekS,KovarH.Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1.Cell Rep2015;10:1082-95 PMCID:PMC4542316

[25] TanabeY,KohsakaS,AkaikeK,KuriharaT,OkuboT,KazunoS,SaitoT.IRE1α-XBP1 inhibitors exerted anti-tumor activities in Ewing's sarcoma.Oncotarget2018;9:14428-43 PMCID:PMC5865680

[26] SelvanathanSP,ErkizanHV,NatarajanTG,YuS,PaulsenMT,WuCH,ürenA.Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing.Proc Natl Acad Sci U S A2015;112:E1307-16 PMCID:PMC4371969

[27] SvobodaLK,SudS,ZebolskyA,ThomasD,LeeHJ,ZhangL,BankheadAR,LjungmanM,GrembeckaJ,LawlorER.Menin regulates the serine biosynthetic pathway in Ewing sarcoma.J Pathol2018;

[28] KedageV,NicholasTR,PlotnikJP,HollenhorstPC.An interaction with Ewing's sarcoma breakpoint protein EWS defines a specific oncogenic mechanism of ETS factors rearranged in prostate cancer.Cell Rep2016;17:1289-301 PMCID:PMC5123826

[29] LinPP,HamelinAC,HealeyJH.Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma.Cancer Res1999;59:1428-32

[30] de AlavaE,AntonescuCR,Pardo-MindánFJ,LadanyiM.Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.Am J Pathol2000;156:849-55

[31] Le DeleyMC,SchaeferKL,KoehlerG,LionT,MarandetJ,PierronG,NesslböckM,DirksenU,LewisIJ,JürgensH.Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial..J Clin Oncol2010;28:1982-8

[32] GroharPJ,Rangel RiveraGO,HaddockS,MaloneyNK,O'NeillM,HuppiK,GehlhausK,BuehlerE,MartinSE.Functional genomic screening reveals splicing of the EWS-FLI1 fusion transcript as a vulnerability in Ewing sarcoma.Cell Rep2016;14:598-610 PMCID:PMC4755295

[33] MinasTZ,JavaheriT,HowarthM,HanJ,SaxB,HongSH,TirodeF,ToretskyJA,KovarH,Sweet-CorderoEA,MorigglR,ürenA.Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model.Oncotarget2017;8:34141-63 PMCID:PMC5470957

[34] Postel-VinayS,TirodeF,ReynaudS,OberlinO,BalletS,KontnyU,PicciP,Patino-GarciaA,LaudK,FroguelP,DozF,ChanockSJ,CoxDG.Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma.Nat Genet2012;44:323-7

[35] GrünewaldTG,Gilardi-HebenstreitP,SurdezD,MirabeauO,TirodeF,PerotG,LucchesiC,OberlinO,VéronAS,LapoubleE,Rio FrioT,BhatiaS,Cancel-TassinG,CoxDG,MachielaMJ,CharnayP.Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite.Nat Genet2015;47:1073-8 PMCID:PMC4591073

[36] GangwalK,HollenhorstPC,HaroldsenSC,BoucherKM,JordeLB,LessnickSL.Microsatellites as EWS/FLI response elements in Ewing's sarcoma.Proc Natl Acad Sci U S A2008;105:10149-54 PMCID:PMC2481306

[37] GuillonN,BoevaV,BarillotE.The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function.PLoS One2009;4:e4932 PMCID:PMC2654724

[38] Kawamura-SaitoM,KanekoK,KandaH,GotohT,FukayamaM,TakizawaT.Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation.Hum Mol Genet2006;15:2125-37

[39] PierronG,LucchesiC,BalletS,PerrinV,DelattreO.A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion.Nat Genet2012;44:461-6

[40] JeonIS,BraunBS,RousselMF,ShapiroDN.A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1.Oncogene1995;10:1229-34

[41] UranoF,YabeH,YoshidaK,HataJ.Molecular analysis of Ewing's sarcoma: another fusion gene, EWS-E1AF, available for diagnosis.Jpn J Cancer Res1998;89:703-11 PMCID:PMC5921883

[42] PeterM,PacquementH,ThomasG,DelattreO.A new member of the ETS family fused to EWS in Ewing tumors.Oncogene1997;14:1159-64

[43] ShingDC,RobertsP,ChinSF,TillmanRM,CullinaneC.FUS/ERG gene fusions in Ewing's tumors.Cancer Res2003;63:4568-76

[44] NgTL,PallenCJ,ClarksonPW,SorensenPH,HorsmanDE.Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV.J Mol Diagn2007;9:459-63 PMCID:PMC1975098

[45] SzuhaiK,de JongD,TankeHJ.The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology.Clin Cancer Res2009;15:2259-68

[46] YamaguchiS,IshikawaY,MukaiH.EWSR1 is fused to POU5F1 in a bone tumor with translocation t(6;22)(p21;q12)..Genes Chromosomes Cancer2005;43:217-22

[47] SumegiJ,NelsonM,PerryD.A novel t(4;22)(q31;q12) produces an EWSR1-SMARCA5 fusion in extraskeletal Ewing sarcoma/primitive neuroectodermal tumor.Mod Pathol2011;24:333-42

[48] MastrangeloT,TornielliS,TestiMA,RadiceP,PilottiS,PierottiMA.A novel zinc finger gene is fused to EWS in small round cell tumor.Oncogene2000;19:3799-804

[49] WangL,ZhengT,CollinsMH,LadanyiM.Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of a novel EWS-SP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions.J Mol Diagn2007;9:498-509 PMCID:PMC1975108

[50] BrohlAS,ChangW,SongY,PatidarR,ChenL,LiaoH,GerardJ,Lopez GuerreroJA,WaiDH,TricheT,MiettinenM,CatchpoolD,WaldmanT.The genomic landscape of the Ewing sarcoma family of tumors reveals recurrent STAG2 mutation.PLoS Genet2014;10:e1004475 PMCID:PMC4091782

[51] SugitaS,TonookaA,TotokiY,AoyamaT,TsukaharaT,ShibataT.A novel CIC-FOXO4 gene fusion in undifferentiated small round cell sarcoma: a genetically distinct variant of Ewing-like sarcoma.Am J Surg Pathol2014;38:1571-6

[52] SpechtK,SungYS,DryS,RichterGH,AntonescuCR.Novel BCOR-MAML3 and ZC3H7B-BCOR gene fusions in undifferentiated small blue round cell sarcomas.Am J Surg Pathol2016;40:433-42 PMCID:PMC4792719

[53] AlholleA,BriniAT,KannappanV,NiblettA,PissalouxD,Maran-GonzalezA,SumathiV,LatifF.Genetic analyses of undifferentiated small round cell sarcoma identifies a novel sarcoma subtype with a recurrent CRTC1-SS18 gene fusion.J Pathol2018;245:186-96

[54] MugneretF,AuriasA.Chromosomes in Ewing's sarcoma.II. Nonrandom additional changes, trisomy 8 and der(16)t(1;16). Cancer Genet Cytogenet1988;32:239-45

[55] ArmengolG,VirolainenM,ValleJ,Asko-SeljavaaraS,ElomaaI,KiviojaAH,TukiainenE,MyklebostO.Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization.Br J Cancer1997;75:1403-9 PMCID:PMC2223493

[56] MauriciD,GrierHE,SerraM.Frequency and implications of chromosome 8 and 12 gains in Ewing sarcoma.Cancer Genet Cytogenet1998;100:106-10

[57] HattingerCM,AmbrosIM,LionT,GadnerH.Demonstration of the translocation der(16)t(1;16)(q12;q11.2) in interphase nuclei of Ewing tumors..Genes Chromosomes Cancer1996;17:141-50

[58] HattingerCM,TarkkanenM,ZielenskaM,KagerL,KnuutilaS,AmbrosPF,BettsDR.Prognostic impact of chromosomal aberrations in Ewing tumours.Br J Cancer2002;86:1763-9 PMCID:PMC2375399

[59] BrissetS,PeterM,OberlinO,AuriasA.CGH analysis of secondary genetic changes in Ewing tumors: correlation with metastatic disease in a series of 43 cases.Cancer Genet Cytogenet2001;130:57-61

[60] DouglassEC,ValentineM,MeyerWH.A second nonrandom translocation, der(16)t(1;16)(q21;q13), in Ewing sarcoma and peripheral neuroectodermal tumor.Cytogenet Cell Genet1990;53:87-90

[61] SandbergAA.Updates on cytogenetics and molecular genetics of bone and soft tissue tumors: Ewing sarcoma and peripheral primitive neuroectodermal tumors.Cancer Genet Cytogenet2000;123:1-26

[62] MackintoshC,García-DomínguezDJ,Llombart-BoschA,ScotlandiK,SciotR,HogendoornPC,KnuutilaS,Debiec-RychterM,de álavaE.1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma.Oncogene2012;31:1287-98

[63] SavolaS,TripathiA,SerraM,KaskiS,ScotlandiK.Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors.BMC Cancer2009;9:17 PMCID:PMC2633345

[64] TirodeF,MaX,Le DeleyMC,ZhangZ,Grossetête-LalamiS,ReynaudS,HedlundE,ChenX,OberlinO,LemmonG,VadodariaB,GutM,MardisER,ShurtleffS,MichonJ,GutI,DyerM,DelattreO.Children's Research Hospital-Washington University Pediatric Cancer Genome Project and the International Cancer Genome Consortium.Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov2014;4:1342-53 PMCID:PMC4264969

[65] CromptonBD,Taylor-WeinerA,KurekKC,KiezunA,ShuklaSA,ThornerAR,LavarinoC,McKennaA,CibulskisK,StojanovP,AmbrogioL,SeepoS,DeFeliceM,Schwarz-CruzY,RiveraMN,FlemingMD,GetzG,StegmaierK.The genomic landscape of pediatric Ewing sarcoma.Cancer Discov2014;4:1326-41

[66] KovarH,AryeeDN,AmbrosP,WindhagerR.Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors.Oncogene1997;15:2225-32

[67] TsuchiyaT,HinoharaS,NoboriT.Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.Cancer Genet Cytogenet2000;120:91-8

[68] WeiG,de AlavaE,HuvosAG,HealeyJH.Prognostic impact of INK4A deletion in Ewing sarcoma.Cancer2000;89:793-9

[69] MaitraA,WeinbergAG.Aberrant expression of tumor suppressor proteins in the Ewing family of tumors.Arch Pathol Lab Med2001;125:1207-12

[70] BrownhillSC,BurchillSA.Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT.Br J Cancer2007;96:1914-23 PMCID:PMC2359978

[71] HonokiK,McEvoyM,TsujiuchiT,TakakuraY.Prognostic significance of p16 INK4a alteration for Ewing sarcoma: a meta-analysis.Cancer2007;110:1351-60

[72] LermanDM,McIlvaineE,HuangD,BeelerN,MarinaNM,BridgeJA,RandallRL.Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.Pediatr Blood Cancer2015;62:759-65 PMCID:PMC4376595

[73] HuangHY,ZhaoZ,HuvosAG,WexlerLH,MeyersP.Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse.J Clin Oncol2005;23:548-58

[74] SolomonDA,Diaz-MartinezLA,ElkahlounAG,ToretskyJA,ShuklaN,SamuelsY,YuH,WaldmanT.Mutational inactivation of STAG2 causes aneuploidy in human cancer.Science2011;333:1039-43 PMCID:PMC3374335

[75] SolomonDA,WaldmanT.Cohesin gene mutations in tumorigenesis: from discovery to clinical significance.BMB Rep2014;47:299-310 PMCID:PMC4163871

[76] LawrenceMS,MermelCH,GarrawayLA,MeyersonM,LanderES.Discovery and saturation analysis of cancer genes across 21 tumor types.Nature2014;505:495-501 PMCID:PMC4048962

[77] MazumdarC,XavyS,ReinischA,CorcesMR,BuenrostroJD,ThomasD,HongWJ,MajetiR.Leukemia-associated cohesin mutants dominantly enforce stem cell programs and impair human hematopoietic progenitor differentiation.Cell Stem Cell2015;17:675-88 PMCID:PMC4671831

[78] van der LelijP,JudeJ,SantosCP,SchlattlA,SchwentnerR,KovarH,WaldmanT,KrautN,ZuberJ.Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts.Elife2017;6:e26980 PMCID:PMC5531830

[79] SheffieldNC,KlughammerJ,SchöneggerA,HadlerJ,GuillemotD,FreneauxP,BouvierR,AmbrosIM,SorzE,de álavaE,StrunkD,Liegl-AtzwangerB,LeithnerA,TerrierP,MichonJ,HolterW,DirksenU,DelattreO,BockC.DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma.Nat Med2017;23:386-95 PMCID:PMC5951283

[80] RiggiN,GillespieSM,BoulayG,RossettiNE,OksuzO,FormeyA,GymrekM,DeshpandeV,HornicekFJ,StamenkovicI,BernsteinBE.EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma.Cancer Cell2014;26:668-81 PMCID:PMC4492343

[81] PatelN,ChenX,GradyWM,BorinsteinSC.DNA methylation and gene expression profiling of Ewing sarcoma primary tumors reveal genes that are potential targets of epigenetic inactivation.Sarcoma2012;2012:498472 PMCID:PMC3447379

[82] AlholleA,GharaneiS,ArrigoniE,GentleD,HirumaT,GrimerR,LatifF.Functional epigenetic approach identifies frequently methylated genes in Ewing sarcoma.Epigenetics2013;8:1198-204

[83] Huertas-MartínezJ,Rello-VaronaS,Almacellas-RabaigetO,Garcia-MonclúsS,BujR,SastreA,SanjuanX,MoranS,GallegoS,García Del MuroX,PeinadoMA,de AlavaE,EstellerM.DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1.Cancer Lett2017;386:196-207

[84] TorchiaEC,RehgJE,BakerSJ.EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice.Mol Cell Biol2007;27:7918-34 PMCID:PMC2169157

[85] LinPP,JinF,DeaversM,LozanoG.EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model.Cancer Res2008;68:8968-75 PMCID:PMC4167779

[86] EmbreeLJ,HicksteinDD.Ewing sarcoma fusion protein EWSR1/FLI1 interacts with EWSR1 leading to mitotic defects in zebrafish embryos and human cell lines.Cancer Res2009;69:4363-71 PMCID:PMC2766243

[87] ParkH,TurnerT,AzumaM.Loss of Ewing sarcoma EWS allele promotes tumorigenesis by inducing chromosomal instability in zebrafish.Sci Rep2016;6:32297 PMCID:PMC4997631

[88] BacabacRG,MullenderMG,Van LoonJJ.Nitric oxide production by bone cells is fluid shear stress rate dependent.Biochem Biophys Res Commun2004;315:823-9

[89] Klein-NulendJ,BakkerAD.Mechanical loading and how it affects bone cells: the role of the osteocyte cytoskeleton in maintaining our skeleton.Eur Cell Mater2012;24:278-91

[90] SantoroM,MenegazBA,MikosAG.Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma.Proc Natl Acad Sci U S A2015;112:10304-9 PMCID:PMC4547215

[91] SantoroM,Lamhamedi-CherradiSE,WuD,LudwigJA.Modeling stroma-induced drug resistance in a tissue-engineered tumor model of Ewing sarcoma.Tissue Eng Part A2017;23:80-9 PMCID:PMC5240012

[92] Marturano-KruikA,YaegerK,ChramiecA,Vunjak-NovakovicG.Biomechanical regulation of drug sensitivity in an engineered model of human tumor.Biomaterials2018;150:150-61

[93] ScotlandiK,NanniP,NicolettiG,SerraM,PicciP.Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice.Cancer Res1998;58:4127-31

[94] VormoorJ,DeckerS,SchäferKL,RübeC,JürgensH.Establishment of an in vivo model for pediatric Ewing tumors by transplantation into NOD/scid mice.Pediatr Res2001;49:332-41

[95] FranziusC,PorembaC,SchäfersK,JürgensH,SchäfersM.Successful high-resolution animal positron emission tomography of human Ewing tumours and their metastases in a murine xenograft model.Eur J Nucl Med Mol Imaging2006;33:1432-41

[96] WangYX,WangS,PollockRE,KleinermanE.Inhibiting platelet-derived growth factor β reduces Ewing's sarcoma growth and metastasis in a novel orthotopic human xenograft model.In Vivo2009;23:903-9

[97] VormoorB,BateyMA,WilsonI,SharmaA,HideIG,VormoorJ,BaconCM.Development of a preclinical orthotopic xenograft model of Ewing sarcoma and other human malignant bone disease using advanced in vivo imaging.PLoS One2014;9:e85128 PMCID:PMC3883696

[98] GoldsteinSD,AlbertCM,LoebDM.An orthotopic xenograft model with survival hindlimb amputation allows investigation of the effect of tumor microenvironment on sarcoma metastasis.Clin Exp Metastasis2015;32:703-15

[99] HongSH,GalliS,PolkT,MahajanA,JenkinsS,ConnorsK,LuC,RodriguezO,AlbaneseC.High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases.Oncotarget2015;6:7151-65 PMCID:PMC4466675

[100] HarrisJC,Kajdacsy-BallaA,ChiuB.Sustained delivery of vincristine inside an orthotopic mouse sarcoma model decreases tumor growth.J Pediatr Surg2016;51:2058-62 PMCID:PMC5138133

[101] VANNoord RA,KrookM,HoenerhoffMJ,LawlorER,NewmanEA.Tissue-directed implantation using ultrasound visualization for development of biologically relevant metastatic tumor xenografts.In Vivo2017;31:779-91 PMCID:PMC5656850

[102] SirsiSR,VlachosF,HernandezSL,JohungTB,ReichsteinAR,WangA,KandelJJ,BordenMA.Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy.Ultrasound Med Biol2012;38:1019-29 PMCID:PMC3348332

[103] van der EntW,TeunisseAF,SzuhaiK,HogendoornPC.Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53.J Pathol2014;233:415-24

[104] El-NaggarAM,ChengH,NegriGL,CorkeryDP,MathersJ,KyleAH,LePardNE,HajeeS,LeprivierG,MinchintonAI,DelattreO,DellaireG,SorensenPH.Translational activation of HIF1α by YB-1 promotes sarcoma metastasis.Cancer Cell2015;27:682-97

[105] FranzettiGA,van der EntW,IrondelleM,DirksenU,de PinieuxG,ChavrierP.Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells.Oncogene2017;36:3505-14 PMCID:PMC5541267

[106] OyamaR,YoshidaA,TakaiY,ShiozawaK,AraiY,ArakiY,KawaiA.Generation of novel patient-derived CIC-DUX4 sarcoma xenografts and cell lines.Sci Rep2017;7:4712 PMCID:PMC5498486

[107] MurakamiT,KiyunaT,LiY,IgarashiK,DeLongJC,HiroshimaY,EckardtMA,FedermanN,ChishimaT,BouvetM,EilberFC.Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.Oncotarget2016;7:47556-64 PMCID:PMC5216960

[108] TK216 in Patients With Relapsed or Refractory Ewing Sarcoma. ClinicalTrials.gov Identifier: NCT02657005. Available from: https://clinicaltrials.gov/ct2/show/NCT02657005 [Last accessed on 23 May 2018].

[109] GorthiA,LorancE,LawrenceLA,IniguezAB,MasamsettiVP,LawlorER,StegmaierK,ChenY.EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.Nature2018;555:387-91

[110] Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma. ClinicalTrials.gov Identifier: NCT01583543. Available from: https://clinicaltrials.gov/ct2/show/NCT01583543 [Last accessed on 23 May 2018].

[111] ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma. ClinicalTrials.gov Identifier: NCT02044120. Available from: https://clinicaltrials.gov/ct2/show/NCT02044120 [Last accessed on 23 May 2018].

[112] KontnyHU,KleinR,MackallCL.Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis.Cell Death Differ2001;8:506-14

[113] LissatA,TsokosM,BraunM,FischP,LongL,MackallCL,KontnyU.Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity.Am J Pathol2007;170:1917-30 PMCID:PMC1899433

[114] de HoogeAS,SantosSJ,RomeoS,EgelerRM,MeliefCJ,LankesterAC.Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways.Clin Cancer Res2007;13:206-14

[115] VerhoevenDH,MooimanEC,ten DamMM,MeliefCJ,EgelerRM,SchilhamMW.NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.Mol Immunol2008;45:3917-25

[116] PahlJH,KwappenbergKM,van TolMJ,SchilhamMW.Antibody-dependent cell lysis by NK cells is preserved after sarcoma-induced inhibition of NK cell cytotoxicity.Cancer Immunol Immunother2013;62:1235-47

[117] GuihoR,GrisendiG,ChatelaisM,HeymannD,RediniF.TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models.Int J Cancer2016;139:2802-11

[118] BerghuisD,BaeldeHJ,EgelerRM,HogendoornPC.Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.J Pathol2011;223:347-57

[119] A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias. ClinicalTrials.gov Identifier: NCT01287104. Available from: https://clinicaltrials.gov/ct2/show/NCT01287104 [Last accessed on 23 May 2018].

[120] Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Sarcomas. ClinicalTrials.gov Identifier: NCT02409576. Available from: https://clinicaltrials.gov/ct2/show/NCT02409576 [Last accessed on 23 May 2018].

[121] Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors. ClinicalTrials.gov Identifier: NCT02100891. Available from: https://clinicaltrials.gov/ct2/show/NCT02100891 [Last accessed on 23 May 2018].

[122] Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors. ClinicalTrials.gov Identifier: NCT01807468. Available from: https://clinicaltrials.gov/ct2/show/NCT01807468 [Last accessed on 23 May 2018].

[123] BerghuisD,VosHI,KloessS,EgelerRM,LankesterAC.Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis.Clin Sarcoma Res2012;2:8 PMCID:PMC3351702

[124] GoodisonS.The cancer testis antigen PRAME as a biomarker for solid tumor cancer management.Biomark Med2012;6:629-32

[125] OsterhoffC,KirchhoffC.Cloning of a human epididymis-specific mRNA, HE6, encoding a novel member of the seven transmembrane-domain receptor superfamily.DNA Cell Biol1997;16:379-89

[126] MoreauxJ,HoseD.STEAP1 is overexpressed in cancers: a promising therapeutic target.Biochem Biophys Res Commun2012;429:148-55

[127] EvansCH,PorterRM,MerghoubT,RobichaudK,LessnickSL,WellsJW.EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors.Clin Cancer Res2012;18:5341-51 PMCID:PMC3463738

[128] BerghuisD,SantosSJ,WiertzEJ,van den ElsenPJ,OttavianoL,DirksenU,MulderA,EgelerRM,JordanovaES,LankesterAC.Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition.J Pathol2009;218:222-31

[129] ParkJH,GonenM,SénéchalB,SauterC,SantomassoB,RoshalM,DavilaM,SadelainM.Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia.N Engl J Med2018;378:449-59

[130] NeelapuSS,BartlettNL,MiklosDB,BraunschweigI,SiddiqiT,TimmermanJM,FriedbergJW,GoyA,SmithMR,FarooqU,MunozJ,CastroJE,ChavezJC,KomanduriKV,JacobsenED,ReaganP,RossiJ,JiangY,EliasM,WiezorekJ.Axicabtagene ciloleucel CAR T-cell therapy in refractory large b-cell lymphoma.N Engl J Med2017;377:2531-44 PMCID:PMC5882485

[131] KailayangiriS,MeltzerJ,LueckeA,TitzeU,LandmeierS,DirksenU,GoshegerG,RossigC.The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.Br J Cancer2012;106:1123-33 PMCID:PMC3304425

[132] Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas. ClinicalTrials.gov Identifier: NCT03356782. Available from: https://clinicaltrials.gov/ct2/show/NCT03356782 [Last accessed on 23 May 2018].

[133] TownJ,HarrisonS,BatailleC,ZhangJ.Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target.Proc Natl Acad Sci U S A2016;113:3603-8 PMCID:PMC4822608

[134] GhisoliM,SchneiderR,LenarskyC,KumarP,RothA,FletcherFA.Pilot trial of vigil immunotherapy in Ewing's sarcoma.J Clin Oncol2015;33 suppl 15:abstr10522

[135] Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer. ClinicalTrials.gov Identifier: NCT01061840. Available from: https://clinicaltrials.gov/ct2/show/NCT01061840. [Last accessed on 23 May 2018].

[136] Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma. ClinicalTrials.gov Identifier: NCT00101309. Available from: https://clinicaltrials.gov/ct2/show/NCT00101309. [Last accessed on 23 May 2018].

[137] A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma. ClinicalTrials.gov Identifier: NCT02511132. Available from: https://clinicaltrials.gov/ct2/show/NCT02511132. [Last accessed on 23 May 2018].

[138] VakkilaJ,MichelowM.Pediatric cancers are infiltrated predominantly by macrophages and contain a paucity of dendritic cells: a major nosologic difference with adult tumors.Clin Cancer Res2006;12:2049-54

[139] LongAH,CuiY,WalkerAJ,El-EtribyR,TsokosMG,MackallCL.Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas.Cancer Immunol Res2016;4:869-80 PMCID:PMC5050151